Two critical barriers, intratumoral pressure and an immunosuppressive environment, limit the delivery and efficacy of immunotherapies in tumors of the liver and pancreas.
We believe that comprehensively addressing these two barriers has the potential to improve the lives of patients with liver and pancreatic tumors. Our therapeutic platform is designed to be used in combination with, and enable, systemic immunotherapies like checkpoint inhibitors.
Learn about how TriSalus aims to address two of the most significant barriers to treatment.
TriSalus takes an integrated approach tailored to the target organ and disease biology, with the goal to overcome two critical barriers: immunosuppression and delivery.
Watch to learn how our platform approach applies to the treatment of liver tumors.
We’re studying the integration of the Pressure-Enabled Drug Delivery™ (PEDD™) method with therapies capable of reactivating immune cells to enable immunotherapies in the liver and pancreas. Our clinical research is focused on bringing this potentially transformative treatment platform to patients.
TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site’s endorsement of TriSalus or this website.
Thank you for visiting our site.